Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» M3 Biotechnology Begins Testing of Alzheimer’s Therapy in Adults with the Disease
M3 Biotechnology Begins Testing of Alzheimer’s Therapy in Adults with the Disease
M3 Biotechnology Begins Testing of Alzheimer’s Therapy in Adults with the Disease
Submitted by
admin
on September 13, 2018 - 9:39am
Source:
CP Wire
News Tags:
M3 Biotechnology
NDX-1017
Alzheimer's disease
Headline:
M3 Biotechnology Begins Testing of Alzheimer’s Therapy in Adults with the Disease
snippet:
NDX-1017 is intented to halt or reverse Alzheimer's
It a completely different mechanism of action than other drug candidates currently in development
NDX-1017 addresses receptors of proteins known as hepatocyte growth factors
Do Not Allow Advertisers to Use My Personal information
